Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Retained Earnings (2016 - 2026)

Akebia Therapeutics has reported Retained Earnings over the past 11 years, most recently at -$1.7 billion for Q4 2025.

  • Quarterly Retained Earnings changed 0.32% to -$1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.7 billion through Dec 2025, changed 0.32% year-over-year, with the annual reading at -$1.7 billion for FY2025, 0.32% changed from the prior year.
  • Retained Earnings was -$1.7 billion for Q4 2025 at Akebia Therapeutics, down from -$1.7 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $9000.0 in Q1 2021 and troughed at -$1.7 billion in Q4 2025.
  • The 5-year median for Retained Earnings is -$1.5 billion (2022), against an average of -$965.6 million.
  • Year-over-year, Retained Earnings skyrocketed 166.67% in 2021 and then crashed 27857783.33% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $6000.0 in 2021, then changed by 0.0% to $6000.0 in 2022, then tumbled by 26815933.33% to -$1.6 billion in 2023, then decreased by 4.31% to -$1.7 billion in 2024, then fell by 0.32% to -$1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Retained Earnings are -$1.7 billion (Q4 2025), -$1.7 billion (Q3 2025), and -$1.7 billion (Q2 2025).